Clostridium difficile infection in solid organ transplant recipients

Current Opinion in Infectious Diseases

Volumn 27, Issue 4, 2014, Pages 336-341

  Honda, Hitoshi ^a   Dubberke, Erik R ^b  

^a TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile infection; Solid organ transplantation; Treatment strategies

Indexed keywords

CLOSTRIDIUM INFECTION; GRAFT RECIPIENT; HUMAN; PEPTOCLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; TRANSPLANT RECIPIENTS;

EID: 84905914596     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000075     Document Type: Review

References (57)

1. Bartlett JG. Detection of Clostridium difficile infection. Infect Control Hosp Epidemiol 2010; 31 (Suppl 1):S35-S37.
2. Number of discharges from US nonfederal, acute care hospitals assigned the International Classification of Disease-9-Clinical Modification (ICD-9-CM) code for CDI (008.45). http://hcupnet.ahrq.gov/HCUPnet.jsp [Accessed 14 February 2014].
3. Boutros M, Al-Shaibi M, Chan G, et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation 2012; 93:1051-1057.
4. Neofytos D, Kobayashi K, Alonso CD, et al. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients. Transpl Infect Dis 2013; 15:134-141.
5. Abecassis M, Bridges ND, Clancy CJ, et al. Solid-organ transplantation in older adults: current status and future research. Am J Transplant 2012; 12:2608-2622.
6. Honda H, Yamazaki A, Sato Y, Dubberke ER. Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe 2014; 25:5-10.
7. Hall AJ, Curns AT, McDonald LC, et al. The roles of Clostridium difficile and norovirus among gastroenteritis-Associated deaths in the United States. Clin Infect Dis 2012; 55:216-223.
8. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55 (Suppl 2):S88-S92.
9. Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:592-600.
10. Lee JT, Kelly RF, Hertz MI, et al. Clostridium difficile infection increases mortality risk in lung transplant recipients. J Heart Lung Transplant 2013; 32:1020-1026.
11. Shah SA, Tsapepas DS, Kubin CJ, et al. Risk factors associated with Clostridium difficile infection after kidney and pancreas transplantation. Transpl Infect Dis 2013; 15:502-509.
12. Len O, Rodríguez-Pardo D, Gavalda J, et al. Outcome of Clostridium difficileassociated disease in solid organ transplant recipients: a prospective and multicentre cohort study. Transpl Int 2012; 25:1275-1281.
13. Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994; 18 (Suppl 4):S265-S272.
14. Pé pin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-Associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-1260.
15. Bobo LD, Dubberke ER, Kollef M. Clostridium difficile in the ICU: the struggle continues. Chest 2011; 140:1643-1653.
16. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-Acquired Clostridium difficile-Associated disease. JAMA 2005; 294:2989-2995.
17. Dubberke ER, Reske KA, Yan Y, et al. Clostridium difficile-Associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45:1543-1549.
18. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390-397.
19. Goldfarb NS, Avery RK, GoormasticM, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71:242-246.
20. Yamani MH, Avery R, Mawhorter S, et al. Hypogammaglobulinemia after heart transplantation: impact of preemptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transpl Infect Dis 2001; 3 (Suppl 2):40-43.
21. Doron S, Ruthazer R, Werner BG, et al. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 2006; 81:697-703.
22. Munoz P, Giannella M, Alcala L, et al. Clostridium difficile associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant 2007; 26:907-914.
23. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441.
24. Kasper AM, Nyazee HA, Yokoe DS, et al. A multicenter study of Clostridium difficile infection-related colectomy. Infect Control Hosp Epidemiol 2012; 33:470-476.
25. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl 1):S12-S18.
26. Dubberke ER, Han Z, Bobo L, et al. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J Clin Microbiol 2011; 49:2887-2893.
27. Planche T1, Wilcox M. Reference assays for Clostridium difficile infection: one or two gold standards? J Clin Pathol 2011; 64:1-5.
28. Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis 2013; 13:936-945.
29. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
30. Litvin M, Reske KA, Mayfield J, et al. Identification of a pseudo-outbreak of Clostridium difficile infection (CDI) and the effect of repeated testing, sensitivity, and specificity on perceived prevalence of CDI. Infect Control Hosp Epidemiol 2009; 30:1166-1171.
31. Dubberke ER, Burdette SD. Clostridium difficile infections in solid organ transplantation. Am J Transplant 2013; 13 (s4):42-49.
32. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-Associated diarrhoea and colitis. Lancet 1983; 2:1043-1046.
33. Page RL 2nd, Klem PM, Rogers C. Potential elevation of tacrolimus through concentrations with concomitant metronidazole therapy. Ann Pharmacother 2005; 39:1109-1113.
34. Pé pin J, Alary M, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-1597.
35. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-1590.
36. Zar FA, Bakkanagari SR, Moorthi K, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-307.
37. Honda H, Dubberke ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol 2014; 30:54-62.
38. Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011; 254:423-429.
39. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-Analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 (Suppl 2):S93-S103.
40. Babakhani F, Bouillaut L, Gomez A, et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55 (Suppl 2):S162-S169.
41. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431.
42. Clutter DS, Dubrovskaya Y, Merl MY, et al. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-Associated diarrhea. Antimicrobial Agents Chemother 2013; 57:4501-4505.
43. O'Horo J, Safdar N. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int J Infect Dis 2009; 13:663-667.
44. Abourgergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011; 56:19-26.
45. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-Associated colitis in adults. Cochrane Database Syst Rev 2008; 23:CD004611; DOI: 10.1002/14651858.CD004611.pub2.
46. Kalima P, Masterton RG, Roddie PH, Thomas AE. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996; 32:165-167.
47. Johnson S, Gerding DN. Fidaxomicin 'Chaser' regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis 2013; 56:309-310.
48. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-Associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44:846-848.
49. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Eng J Med 2013; 368:407-415.
50. Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant 2014; 14:477-480.
51. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 (Suppl 1):S81-S92.
52. Sethi AK, Al-NassirWN, Nerandzic MM, et al. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol 2010; 31:21-27.
53. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204-210.
54. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990; 88:137-140.
55. Landelle C1, Verachten M, Legrand P, et al. Contamination of healthcare workers' hands with Clostridium difficile spores after caring for patients with C. difficile infection. Infect Control Hosp Epidemiol 2014; 35:10-15.
56. Edmonds SL, Zapka C, Kasper D, et al. Effectiveness of hand hygiene for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol 2013; 34:302-305.
57. Vajravelu RK, Guerrero DM, Jury LA, Donskey CJ. Evaluation of stethoscopes as vectors of Clostridium difficile and methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2012; 33:96-98.